GlassScriptPhysician profile
Carly J Miller
NPI 1619180411
$4,924.75
in general payments reported to CMS, 2019-2025
31 companies · $571 in 2025
The $571 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $517 · 2021: $1,050 · 2022: $822 · 2023: $1,005 · 2024: $469 · 2025: $571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,045.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,045.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,178.10 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $778.04 | 2019-2025 | Trintellix |
| Vanda Pharmaceuticals INC. | $474.76 | 2019-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $380.04 | 2019-2025 | Rexulti, Nuedexta |
| Lundbeck LLC | $288.83 | 2019-2023 | Rexulti, Vyepti |
| Bausch Health US, LLC | $260.80 | 2019-2025 | Aplenzin, Wellbutrin |
| Axsome Therapeutics, INC. | $189.25 | 2022-2025 | Auvelity, Sunosi |
| Boston Scientific Corporation | $180.39 | 2019-2024 | Bionic Navigator |
| Allergan, INC. | $136.67 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $122.48 | 2019-2022 | |
| Idorsia Pharmaceuticals US INC | $111.24 | 2023-2024 | Quviviq |
| Orexo US, INC. | $101.03 | 2019-2021 | |
| Amgen INC. | $94.91 | 2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $82.62 | 2022 | |
| Scilex Pharmaceuticals INC. | $72.88 | 2020-2023 | Ztlido |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $62.79 | 2019-2025 | Relistor |
| Supernus Pharmaceuticals, INC. | $61.41 | 2022-2023 | Qelbree |
| Alkermes, INC. | $47.71 | 2022-2023 | Aristada, Lybalvi |
| E.R. Squibb & Sons, L.L.C. | $42.20 | 2025 | Cobenfy |
| Biohaven Pharmaceutical Holding Company LTD. | $41.58 | 2022 | |
| Bioventus LLC | $31.85 | 2024 | Durolane |
| Almatica Pharma LLC | $28.40 | 2021-2022 | |
| Neos Therapeutics, LP | $26.84 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.80 | 2019 | |
| Bioxcel Therapeutics, INC. | $17.43 | 2023 | Igalmi |
| Redhill Biopharma INC. | $15.87 | 2021 | |
| Biodelivery Sciences International, INC. | $15.21 | 2021 | |
| Alfasigma USA, INC. | $14.99 | 2020 | |
| Arbor Pharmaceuticals, INC. | $14.96 | 2021 | |
| Spr Therapeutics, INC | $13.18 | 2024 | Sprint Pns System |
| Zyla Life Sciences, INC. | $12.49 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carly Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.